This study explored the effects of long-term photobiomodulation on the glial and neuronal organisation in the striatum of aged mice. Mice aged 12 months were pre-treated with photobiomodulation (670nm) for 20 minutes per day, commencing at 5 months old and continued for 8 months. We had two control groups, young at 3 and aged at 12 months old; these mice received no treatment. Brains were aldehyde-fixed and processed for immunohistochemistry with various glial and neuronal markers. We found a clear reduction in glial cell number, both astrocytes and microglia, in the striatum after photobiomodulation in aged mice. By contrast, the number of two types of striatal interneurones (parvalbumin + and encephalopsin + ), together with the density of striatal dopaminergic terminals (+ their midbrain cell bodies), remained unchanged after such treatment. In summary, our results indicated that long-term photobiomodulation had beneficial effects on the ageing striatum by reducing glial cell number; further, that this treatment did not have any deleterious effects on the neurones and terminations in this nucleus.
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INTRODUCTION
A characteristic feature of the central nervous system in ageing is an activation of glial cells (Lynch et al., 2014; Soreq et al., 2017) . For example, many previous studies have reported a marked aged increase in the number of glial cells, both astrocytes and microglia, across the central nervous system (Beach et al., 1989; Unger, 1998) . For both types of glial cells, there is also an increase in their size and immunohistochemical expression of various markers (Beach et al., 1989; Unger, 1998; Cotrina and Nedergaard, 2002; Conde and Streit, 2006; Begum et al., 2013) .
A further feature of ageing is that, in contrast to the increase in glial cell number, there is a progressive loss of neurones. This loss manifests after a series of intrinsic molecular changes within the neurones leading to dysfunction and ultimately, death. Further, such changes render ageing neurones more susceptible to insult, whether by environmental toxin or genetic mutation, such as in Alzheimer's or Parkinson's disease. In fact, ageing is a major risk factor for both these neurodegenerative disorders (Linnane et al., 1989; Kujoth et al., 2005; Balaban et al., 2005; Salvadores et al., 2017) .
There is general agreement that a pivotal part of the intrinsic change leading to glial and neuronal ageing and death is dysfunction of the mitochondria. Mitochondria drive neuronal function by producing ATP (adenosine triphosphate) and with ageing, this ability diminishes. This is associated with an increase in toxic reactive oxygen species, oxidative stress and subsequent neuronal death (Linnane et al., 1989; Kujoth et al., 2005; Balaban et al., 2005; Salvadores et al., 2017) .
In view of these key features of ageing, the development of treatments that target a reduction of gliosis and the protection of mitochondria in neurones have generated much interest (Chaturvedi and Beal, 2008) . In this context, recent studies have shown that relatively short-term exposure to red to infrared light (λ=600-1070nm), or photobiomodulation, not only reduces gliosis markedly (Begum et al., 2013; El Massri et al., 2016a,b) but also improves mitochondrial function (Eells et al., 2004; Karu, 2010; Rojas and M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT many other neural centres, from the cerebral cortex to the thalamus and to all the other nuclei in the basal ganglia (Parent and Hazrati, 1995) . Further, except for features of the dopaminergic system (Darbin, 2012) , few studies have explored the glial and neuronal organisation of the striatum, together with the greater basal ganglia, in ageing. Indeed, no previous study has explored the effects of photobiomodulation in this key brain area in ageing. To this end, we examined several cellular structures of the striatum, namely, the ). In general, by using these striatal structures as examples, we aimed to gain insight into the overall age-related changes evident in the basal ganglia and the impact after photobiomodulation.
MATERIALS & METHODS
2.1. Subjects: Male C57BL/6 mice (n=16) mice were housed on a 12hr light/dark cycle with unlimited access to food and water. Animals were either young at 3 or aged at 12 months old (examining animals at only one stage for young (3 months) and using 12 months as aged is common (eg, Vacano et al., 2018) ). All experiments were approved by the Animal Ethics Committee of the University College London and Home Office licensed procedures conforming to the UK Animal Licence Act (1986). We had three groups of mice; 3m (aged 3 months, n=5; young controls, with no photobiomodulation), 12m (aged 12 months, n=6; old controls, with no photobiomodulation) and 12m+PBM (aged 12 months, n=5; photobiomodulation-treated) 2.2. Photobiomodulation: Animals in the 12m+PBM group were treated with photobiomodulation (670nm) for 20 minutes per day. This treatment occurred in the morning. Treatment commenced when the animals were 5 months old and continued for 8 months, up until the animals reached 12 months of age. Our rationale for commencing treatment at 5 months was that at this age, mice in the wild are considered "old", but in other respects "normal". We hence have used fully mature mice (5 months) and mapped progress through to an older age (12 months), recording any changes to this progress with or without photobiomodulation.
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hydroxylase (TH; 1:500; T8700 Sigma; to label dopaminergic terminals), rabbit anti-encephalopsin (Eno; 1:500; ab75285; Abcam; to label striatal neurones) or mouse anti-parvalbumin (Pv; 1:3000; P3088; Sigma; to label striatal neurones) followed by biotinylated goat anti-rabbit or anti-mouse IgG and then streptavidin-peroxidase complex (71-00-19; KPL). In addition, sections of midbrain were incubated anti-TH to label the dopaminergic cells that project to the striatum and these were processed further as described above. Finally, all sections were reacted in a 3,3'-diaminobenzidine tetrahydrochloride solution (D3939; Sigma) and then coverslipped. For controls, sections were processed as described above except that no primary antibody was used. These control sections were immunonegative. For cell analysis, the number of immunoreactive cells in the striatum (and midbrain) were estimated using the optical fractionator method (StereoInvestigator, MBF Science), as described previously (Shaw et al., 2010; El Massri et al., 2016a,b) . We also measured the density of TH 
RESULTS
Our results will explore the age-related changes, and the effects of photobiomodulation, in the striatum. The changes in glia, neurones and terminal patterns will be considered separately.
Glia: There were marked changes evident in both types of glial cells following long-term photobiomodulation in the striatum of aged mice. Fig 1A shows a graph of the estimated total number of GFAP + astrocytes in the striatum in the different experimental groups. There were clear differences in cell number between the different groups ( Fig 1A; ANOVA: F= 14; p<0.001). There was a ~60% increase in the number of GFAP + astrocytes between the 3m and 12m groups (Tukey-Kramer: p<0.0001). In the 12m+PBM group, the number of astrocytes was much lower than the 12m group (Tukey-Kramer: p<0.01), being similar to the 3m group (Tukey-Kramer: p>0.05). In terms of morphology and overall immunoreactivity, GFAP + cells of the 12m (Fig 1C) tended to be much larger and more strongly-labelled than those in the 3m (Fig 1B) and   12m+PBM (Fig 1D) groups. They appeared "activated". For the IBA1 + microglial cells, there were differences M A N U S C R I P T
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in cell number between the different groups also (Fig 1E; ANOVA: F= 11; p<0.001). Although there were no differences in the number of IBA1 + microglia between 3m and 12m groups (Tukey-Kramer: p>0.05), there was a ~50% reduction in cells between the 12m (and 3m) and 12+PBM groups (Fig 1E; p<0.01). In terms of morphology, we found no differences evident among IBA1 + microglia of the 3m (Fig   1F), 12m (Fig 1G) and 12m+PBM (Fig 1H) groups; we encountered no "activated", amoeboid-like cells, with all cells having the classical resting-state morphology. In summary, we found that long-term photobiomodulation had a major effect on the number of glial cells in the striatum of older animals.
Neurones:
In contrast to the findings on the glial cells, we found no major changes after long-term photobiomodulation in the two distinct neuronal types we examined, namely those that express parvalbumin or encephalopsin. For parvalbumin + cells, previous studies have reported these form a subgroup of the GABAergic (γ-aminobutyric acid) interneurones in the rodent striatum (Kawaguchi et al., 1995) . Overall, there were clear differences in the numbers of parvalbumin + cells between the experimental groups (Fig 2A; ANOVA: F= 31; p<0.0001), due mainly to the ~50% reduction in their number between the 3m and 12m groups (Tukey-Kramer: p<0.0001). There were no major differences however, between the 12m and 12m+PBM group (Tukey-Kramer: p>0.05). In terms of morphology and overall immunoreactivity, parvalbumin + cells of the 3m (Fig 2B), 12m (Fig 2C) and 12m+PBM (Fig 2D) groups, were very similar. For the encephalopsin + cells, these have been localised to a group of interneurones also, but to a distinct set, namely the cholinergic interneurones (El Massri et al., 2017) . Unlike the parvalbumin + cells, there were no substantial differences in the numbers of encephalopsin + cells between the experimental groups ( Fig 2E; ANOVA: F= 0.3; p=0.77), in particular between the 3m and 12m groups and between the 12m and 12m+PBM groups (Tukey-Kramer: p>0.05). In terms of morphology and patterns of immunoreactivity, there were no major differences evident among encephalopsin + cells of the 3m (Fig 2F), 12m (Fig 2G) and 12m+PBM (Fig 2H) groups. In summary, for the two types of striatal interneurones we examined in this study, we found that long-term photobiomodulation had no effect on their number in older animals.
Terminal patterns: As with the two types of striatal interneurones, we found no substantial differences in the mean density of striatal TH + terminals in the three experimental groups used in this study (Fig 3A; ANOVA: F= 1.1; p=0.35). In each group, namely 3m (Fig 3B), 12m (Fig 3C) and 12m+PBM (Fig 3D) , strongly-labelled TH + terminals were seen across the nucleus, with no major zones of lighter or no labelling.
We also examined the number of TH (Fig 3E; ANOVA: F= 0.2; p=0.83), namely 3m (Fig 3F), 12m ( Fig G) and 12m+PBM (Fig 3H) . In summary, neither ageing nor long-term photobiomodulation had any effect on the dopaminergic system of mice, with no changes being recorded in the density of TH + terminations in the striatum and in the number of TH + cells in the midbrain SNc.
DISCUSSION
The aim of this study was to explore the effects of long-term photobiomodulation on the glial and neuronal organisations of the striatum in ageing. In general, our results indicated that in mice aged 12 months, photobiomodulation had a greater impact on reducing glial numbers than on increasing neuronal ones;
further, that this treatment had no deleterious effects on either type of brain cell. The latter is a key safety issue, particularly with regard to the use of this therapy in humans. Specifically, we found a clear reduction in the number of glial cells, both astrocytes and microglia, in the striatum after long-term photobiomodulation. By contrast, the number of two types of interneurones, together with the density of a major terminal input to the striatum, remained unchanged after long-term photobiomodulation. These findings will be the focus of the Discussion below.
Our most striking finding was that long-term photobiomodulation generated a change in the number of glial cells in ageing. These changes in number can serve as important indicators as to the overall impact of photobiomodulation in the ageing and diseased brain (eg, Beach et al., 1989; Mouton et al., 2001; Ramírez et al., 2002; Fernagut et al., 2004) and have been used by many previous authors exploring different issues and therapeutic methods in the aged and diseased neural system (eg, Bakalian et al., 1991; Ohm et al., 1997; Pelvig et al., 2008; Fabricius et al., 2013; El Massri et al., 2016a,b) . For both glial cell types, astrocytes and microglia, we found fewer cells in the striatum of the 12m+PBM than in the 12m group (Fig   1) . For the astrocytes, their number in the 12m+PBM group was not only much lower than the 12m group, but it was similar to the 3m group, indicating that photobiomodulation offset almost completely the age-related astrogliosis in the striatum. The astrogliosis we found in the striatum has also been noted in other regions of the ageing brain (Beach et al., 1989; Unger, 1998; Cotrina and Nedergaard, 2002; Conde and Streit, 2006) and retina (Ramìrez et al., 2001) . Further, photobiomodulation has been shown to reduce GFAP expression in astrocytes (and Müller cells) in the aged retina (Begum et al., 2013) . It remains to be determined whether the reduction in the number of GFAP 
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we suggest that the bulk of the changes we found were due to a functional down-regulation of GFAP expression. Further, whether this down-regulation of GFAP was in response to changes in striatal neuronal numbers or a direct impact on the astrocytes themselves is not clear (El Massri et al., 2016b) . From our results, where we noted no photobiomodulation-induced changes in the number of two neuronal types (see below), one would assume that there was a direct impact of photobiomodulation on the astrocytes, rather than as a secondary response to a change in neurone number. However, a much more exhaustive investigation of the changes in the number of many different types of striatal neurones, well beyond the scope of this study, would establish if this is the case. For the microglia, unlike the astrocytes, we found no clear increase in their numbers between 3m and 12m group, indicating no evidence for microgliosis in our model; further we found no activated "amoeboid-like" cells in the striatum of the 12m group. Previous studies have reported that different brain regions and the retina all show signs of microgliosis, but at different stages of ageing. For example, the midbrain SNc develops microgliosis in mice aged 12 months (Schumm et al., 2012) , while the cerebral cortex (Tremblay et al., 2012) , and perhaps the retina also (Damani et al., 2011; Ma and Wong, 2016) , develop microgliosis at a later stage, from 18-24 months.
Following, it is likely that the striatum is one of those brain regions, like the cerebral cortex for example, that develops microgliosis at a later stage in ageing, well after 12 months of age in mice. Finally, we found that the 12+PBM group, rather curiously, had many fewer microglia cells than in the 12m, as well as the 3m, group. The significance of this finding is not clear, but we suggest that photobiomodulation may have had an inhibitory effect on microgliosis in the striatum, that this treatment served as a prophylaxis to microglial hypertrophy (Zecha et al., 2016) .
In contrast to the effect on glial cells in the striatum of aged mice, our results showed that long-term photobiomodulation had no impact on the two types of striatal interneurones examined in this study, namely the parvalbumin + and encephalopsin + cells. For both neuronal types, there were no differences in their number between the 12m and 12m+PBM groups (Fig 2) . The result was particularly relevant for the number of parvalbumin + cells that, unlike the number of encephalopsin + cells, showed a marked decrease from the 3m to the 12m group. This reduction was not mitigated by photobiomodulation (Fig 2) .
The beneficial outcomes of photobiomodulation are thought to involve an activation of a photoacceptor, such as cytochrome c oxidase, leading to an increase in electron transfer in the respiratory chain within the mitochondria and increased ATP production (Eells et al., 2004; Karu, 2010; Rojas and Gonzalez-Lima, 2011; Begum et al., 2013; Gkotsi et al., 2014; Khan and Arany, 2015; Hamblin, 2016; Sivapathasuntharam et al., M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 2017; Weinrich et al 2017) . This, in turns, triggers a cascade of secondary downstream signalling pathways that collectively stimulate intrinsic neuroprotective mechanisms (Rojas and Gonzalez-Lima, 2011; Khan and Arany, 2015; Hamblin, 2016) . With regard to our findings here, our long-term photobiomodulation may not have been efficient in activating these beneficial mechanisms and to prevent neuronal loss in ageing, at least among the parvalbumin + cells of the striatum. Perhaps a different dosage may have been more efficient; for various neurological disorders, from Alzheimer's to Parkinson's disease, dosage has been reported to be important in effectiveness of photobiomodulation as a neuroprotective agent (Rojas and Gonzalez-Lima, 2011; Khan and Arany, 2015; Hamblin, 2016) , and the same may be the case in ageing.
Our analysis of the dopaminergic system, in terms of terminals in the striatum and cell bodies in the midbrain SNc, indicated that it remained stable in mice aged 12 months. These findings are consistent with previous ones in animals of this age (Schumm et al., 2012) . Further, our results indicated that, as with the striatal interneurones, long-term photobiomodulation had no deleterious effects on these key structures of the basal ganglia. After 8 months of daily exposure, the density of dopaminergic terminations and the number of their cell bodies in the 12m and 12m+PBM groups were near identical (Fig 3) . This result has positive implications for the safety of long-term photobiomodulation on the dopaminergic neurones (and striatal interneurones; see above) and for future use in Parkinson's disease patients (Mitrofanis, 2017).
In conclusion, our results indicated that long-term photobiomodulation had beneficial effects on the ageing brain. This treatment was effective in reducing glial cell number and did not have any deleterious effects on the neurones and terminations in the striatum. That this treatment was not toxic to these cells after such a long-term exposure in the aged brain is a key safety issue, particularly when considering use in humans.
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